UNITED GUARDIAN INC. - 10-K Filing Summary
Business Context and Reporting Period
Company: United-Guardian, Inc. (Ticker: UG)
Filing Type: Annual Report on Form 10-K
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: A Delaware corporation manufacturing specialty cosmetic, personal care, and sexual wellness ingredients, as well as healthcare products including pharmaceuticals (Renacidin) and medical lubricants. The company operates as a single segment with facilities in Hauppauge, New York.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Net Sales | $10,545,468 | $12,181,971 |
| Gross Profit Margin | 49% | 53% |
| Net Income | $2,105,738 | $3,250,875 |
| Earnings Per Share (Basic/Diluted) | $0.46 | $0.71 |
| Operating Cash Flow | $1,966,819 | $3,466,251 |
| Working Capital | $10,532,076 | $10,751,082 |
| Current Ratio | 7.3 to 1 | 6.6 to 1 |
| Total Assets | $13,108,579 | $13,797,335 |
| Debt | None reported | None reported |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 13% to $10.5 million. This was primarily driven by a 45% drop in cosmetic ingredient sales ($3.0M vs $5.4M), largely due to a 54% decrease in sales to the largest distributor, Ashland Specialty Ingredients (ASI), attributed to decreased demand in Asia and ASI overstocking.
- Pharmaceutical Growth: Pharmaceutical net sales increased 15% to $5.4 million, driven by increased orders from wholesalers following a temporary manufacturing shutdown in early 2024.
- Margin Compression: Gross profit margin declined from 53% to 49%. This was caused by the shift in sales mix toward lower-margin pharmaceuticals and higher per-unit overhead costs due to reduced cosmetic production volumes.
- Investment Income: Decreased 16% to $365,308 due to lower interest rates and reduced average investment balances.
- Dividends: The company maintained a dividend policy, paying $0.60 per share in 2025 ($0.35 in Q1 and $0.25 in Q3).
Guidance, Outlook, and Risks
- New Distribution Agreements: In January 2026, the company signed an agreement with Brenntag Specialties to distribute the new "Natrajel" sexual wellness line in the US, Canada, Mexico, and France. No sales of this line occurred in 2025.
- Renegotiation with ASI: The distribution agreement with ASI expired in December 2023. Negotiations for a new contract are ongoing, with a goal to finalize in the first half of 2026. The company continues to fulfill orders during negotiations.
- Regulatory Changes: The company is subject to the new Medicare Part D Manufacturer Discount Program (MDP). While qualified as a "specified small manufacturer" for a phase-in period (reducing rebates in 2025/2026), full rebate liabilities are expected to increase significantly by 2031.
- Subsequent Event: A settlement was reached with the contract manufacturer for Renacidin regarding a 2023/2024 facility shutdown. The manufacturer will supply approximately $300,000 of product at no cost, expected to be recognized in Q1 2026.
- Risks: Concentration of credit risk (top 4 customers accounted for 74% of gross sales); reliance on a single contract manufacturer for Renacidin; and potential impacts from global trade tariffs and supply chain instability.
Investor Verification Checklist
- ASI Contract Status: Verify the timeline and terms of the renegotiated distribution agreement with Ashland Specialty Ingredients, given the significant sales drop in 2025.
- Renacidin Supply Chain: Confirm the stability of the contract manufacturer relationship following the 2023/2024 shutdown and the execution of the $300k settlement.
- Medicare Rebate Liability: Review the long-term financial impact of the MDP phase-in schedule, specifically the projected increase in rebate liabilities post-2026.
- Sexual Wellness Launch: Monitor the commercial performance of the new Natrajel line and the effectiveness of the Brenntag distribution partnership in 2026.
- Cash Flow Sustainability: Assess the ability to maintain dividend payments given the 43% decline in operating cash flow and the shift in sales mix.